This free climber will leave your jaw dropped with his freakishly talented training technique
This free climber will leave your jaw dropped with his freakishly talented training technique
Cristiano Ronaldo will be able to stay at home in Turin when Portugal begins its World Cup qualifying program at a neutral venue in Italy because of the COVID-19 pandemic. The Portuguese soccer federation said Thursday its “home” game against Azerbaijan on March 24 was moved to the home of Juventus, Ronaldo's club. Portugal's players, including several with Premier League clubs, face quarantine issues upon returning if they visit their home country.
Around the country, the U.S. Department of Labor estimates more than $63 billion in fraudulent claims have been filed since the beginning of the pandemic.
The "Optical Microscopes - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
Investors looking to recover from last week's bond-market selloff may want to brace for another bout of volatility.
The Urology Laser Market was valued at approximately USD 944. 79 million in 2020 and is expected to witness a revenue of USD 1,295. 24 million in 2026, with a CAGR of 5. 51% over the forecast period.New York, March 04, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Urology Laser Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" - https://www.reportlinker.com/p06030495/?utm_source=GNW COVID-19 pandemic is expected to have a significant impact on the growth of the studied market. In addition to the effects of the Coronavirus on public health, there is the collateral effect of near?universal disruption and cancelation of surgical services, which had unprecedented implications for surgical services and patients with surgical conditions. Operating theaters and anesthesia machines are being temporarily converted to respiratory support units in regions with a high disease burden. Additionally, as per the study titled “Elective surgery cancellations due to the COVID-19 pandemic: global predictive modeling to inform surgical recovery plans”, published in May 2020, approximately 2.5 million urological benign surgeries were reported to be canceled during the peak disruption by COVID-19. Over the coming weeks, healthcare workers, including urologists, may face increasingly difficult challenges. Thus, they should adopt the triage strategy to avoid the wasting of medical resources. They should also endorse sufficient protection policies to guard against infection when dealing with COVID-19 patients. Thus, considering the above-mentioned factors, the pandemic is likely to have a short-term negative impact on the market studied, due to the postponed elective surgeriesOne of the major factors driving the market studied is the high prevalence of urologic conditions across the world. The prevalence of urinary incontinence is more in women than in men. According to the Global Forum on Incontinence, 2018, 12.4% of all women and 5% of all men, i.e., 303 million and 121 million, respectively, are affected by urinary incontinence worldwide. Also, the rising adoption of minimally invasive surgical procedures in holmium systems, as well as thulium laser treatment systems, is one of the major factors propelling the market for urology lasers. These systems offer several benefits, such as greater efficiency, safety, and rapid recovery, resulting in increased demand for thulium and holmium systems.Furthermore, laser procedure provides certain benefits, such as faster recovery, shorter hospital stays, decreased blood loss, and lower overall body pain resulting from smaller incisions. Hence, the reliability and safety features of these systems are expected to drive market growth. Additionally, key players in the market studied are focusing on frequent product developments and approvals, which may substantially drive the market during the forecast period. For instance, in June 2020, Olympus launched its new Soltive SuperPulsed Laser System (Soltive Laser System), a new application of thulium fiber laser technology designed for stone lithotripsy and soft tissue applications. Thus, such factors are likely to drive the growth of the market studied, during the forecast period.Key Market TrendsBenign prostatic hyperplasia (BPH) is Expected to Hold the Largest Revenue in the Application Segment in Urology Laser MarketBenign prostatic hyperplasia is a medical condition involving the enlargement of the prostate gland, and it is highly prevalent in males. It is a non-cancerous growth of the prostate gland originating from the uncontrolled expansion of prostate cells. The common symptoms associated with BPH include frequent urination, urine initiation difficulties, a weak urinary system, and the inability to empty the urinary bladder.The majority of the benign prostatic hyperplasia patient population is elderly, and as the geriatric population is rising, the burden of this disease is also increasing, boosting the demand for laser treatment in this segment. According to the World Ageing Population report, in 2019, around 703 million people aged 65 years and above were living across the world. Over the next three decades, this older population is expected to steadily increase and more than double, to reach over 1.5 billion by 2050. Eastern and South-eastern Asia are expected to observe the largest increase by about 312 million in the coming years compared to any other region.Furthermore, according to the study titled, ‘’The prevalence and associated factors of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in aging males’’, published in May 2020, the disease prevalence was the highest in elderly patients (aged 70 years and above), of about 22.7%. Also, several new laser treatments are being studied to improve the outcome in patients. For instance, in December 2020, a group of surgeons from St Vincent’s Private Hospital, Australia, were working with a 152-watt laser, which is based on virtual basket technology and is designed in Italy for the treatment of benign prostatic hyperplasia. Such instances are expected to support the market growth.Additionally, as the post-COVID-19 scenario is resuming gradually, the healthcare providers are shifting their focus toward BPH treatment, and an optimistic approach toward active collaboration for BPH treatments is expected. This will boost the market studied. Hence, positive growth is expected in this segment over the forecast periodNorth America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast PeriodNorth America currently dominates the market for urology laser devices and is expected to continue its stronghold for a few more years owing to the increasing prevalence of urolithiasis, BPH, and other urology-related disorders. The United States is expected to be the largest market for urology lasers in the North American region owing to the increasing prevalence of urological disorders, such as bladder cancer and urinary incontinence, and the rising preference for minimally invasive procedures due to less operative time and fewer complications.The emergence of novel technologies, along with their adoption, is helping the market studied to grow in the United States. The rising healthcare expenditure is the prime factor responsible for the growth of the healthcare sector in the country. According to the American Cancer Society, the estimated new cases of bladder cancer in Americans in 2020 were around 81,400 (Men: 62,100, Women: 19,300) and about 17,980 deaths occurred due to it in the United States.According to the US Census Bureau 2019 estimates, the 65 and older population increased by 3.2% from 2018 to 2019, and it is expected to rise from around 56 million in 2020 to 94 million by 2060. The older population is often susceptible to urological diseases, especially urinary incontinence, which is propelling the market growth. Laser therapy seems to be a promising alternative approach to urinary incontinence in women. The country has well-established companies that are continuously engaged in the development of new products. In 2019, the Litho EVO laser system developed by Quanta System received a US FDA (United States Food and Drug Administration) approval for use in urological surgeries. Hence, the aforementioned factors are expected to contribute to the growth of the urology laser market in the region.Competitive LandscapeThe urology laser market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Olympus Corporation, Boston Scientific Corporation, Richard Wolf GmbH, Cook Group, Medtronic, Biolitec AG and Lumenis Ltd. The key players are involved in varied strategic alliances such as acquisitions and collaborations, along with new product launches to withstand their position in the global market.Reasons to Purchase this report:- The market estimate (ME) sheet in Excel format- 3 months of analyst supportRead the full report: https://www.reportlinker.com/p06030495/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
Los Angeles, California--(Newsfile Corp. - March 4, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Datto Holding Corp. (NYSE: MSP) ("Datto" or "the Company") for violations of the securities laws.If you are a shareholder who suffered a loss, click here to participate.We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, ...
Mar. 4—COMMERCE — The Texas A&M University-Commerce women's basketball team loves to face man-to-man defenses. "The last time we faced a man we scored 110 points," said Lions coach Jason Burton. But the Lions showed they can also handle a zone defense in their 77-63 victory over Oklahoma Christian on Tuesday in the opening round of the Lone Star Conference tournament. The Lions, now 12-2 for ...
Heart inflammation is uncommon in pro athletes who’ve had mostly mild COVID-19 and most don’t need to be sidelined, a study conducted by major professional sports leagues suggests. The results are not definitive, outside experts say, and more independent research is needed. The coronavirus can cause inflammation in many organs, including the heart.
The Dow Jones Industrial Average slid from record highs at the end of February, as the current stock market pullback continues. The best Dow Jones stocks to buy and watch in March 2021 are Apple, Disney, Microsoft and Visa.
Gov. Greg Abbott announced Tuesday he was rolling back Texas’ mask mandate and reopening the state “100%.”
While “Nomadland’s” Joshua James Richards and “Mank’s” Erik Messerschmidt lead the field for the cinematography Oscar race, this is a deep competition, and although there are some women contending, they are once again a minority. As for the forefront of the race, Richards won the Golden Frog from the prestigious Camerimage festival, the National Board […]
The Giants need to bolster their offensive firepower and the NFL Draft should have enough top options to do that at No. 11. But what if Dave Gettleman isn't thinking offense first with that pick? These should be the only defensive ones he spends it on come April.
The huge jump came after Amgen (NASDAQ: AMGN) announced plans to acquire Five Prime for close to $1.9 billion. Regardless, today's announcement is certainly great news for Five Prime Therapeutics shareholders. Investors appear to also think it's a good move for Amgen.
Los Angeles, California--(Newsfile Corp. - March 4, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or "the Company") for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.If you are a shareholder who suffered a loss, click here to participate.We also ...
4 March 2021 Aéroports de Paris SAInformation regarding the voting rights and shares as of 28 February 2021Statement according to Article L. 233-8-II of the French Commercial Code and 223-16 of the General Regulations of the “Autorité des Marchés Financiers” ISIN: FR0010340141Ticker: ADPListing place: Euronext ParisMarket: Euronext Paris - Compartment A – SRD Date Total number of shares Total number of gross voting rights Total number of net voting rights1 28/02/2021 98,960,602 171,787,891 171,771,831 1 Gross voting rights less shares without voting rights Investor Relations: Audrey Arnoux, Head of Investor Relations +33 6 61 27 07 39 - firstname.lastname@example.orgPress contact: Lola Bourget, Head of Medias and Reputation Department +33 1 74 25 23 23Groupe ADP develops and manages airports, including Paris-Charles de Gaulle, Paris-Orly and Paris-Le Bourget. In 2020, the group handled through its brand Paris Aéroport 33.1 million passengers and 1.8 million metric tons of freight and mail at Paris-Charles de Gaulle and Paris-Orly, and more than 96.3 million passengers in airports abroad. Boasting an exceptional geographic location and a major catchment area, the group is pursuing its strategy of adapting and modernizing its terminal facilities and upgrading quality of services; the group also intends to develop its retail and real estate businesses. In 2020, group revenue stood at €2,137 million and net result attributable to the Group at -€1,169 million. Registered office: 1, rue de France, 93 290 Tremblay-en-France. Aéroports de Paris is a public limited company (Société Anonyme) with share capital of €296,881,806. Registered in the Bobigny Trade and Company Register under no. 552 016 628. groupeadp.fr Attachment Aéroports de Paris SA - Voting rights as of 28 february 2021
The "Augmented and Mixed Reality Market by Technology, Infrastructure, Devices, Solutions, Apps and Services in Industry Verticals 2021 - 2026" report has been added to ResearchAndMarkets.com's offering.
Los Angeles, California--(Newsfile Corp. - March 4, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Magnite, Inc. (NASDAQ: MGNI) ("Magnite" or "the Company") f/k/a Telaria, Inc. (NYSE: TLRA) and/or Rubicon Project (NASDAQ: RUBI) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. ...
French public limited company (société anonyme) with share capital of €1,478,800,602.50Registered office: 1 cours Ferdinand de Lesseps, F-92500 Rueil Malmaison552 037 806 RCS Nanterrewww.vinci.com_____________________________________________________ Description of the 2021-2022 treasury share buy-back programmesubmitted by the Board of Directorsfor the approval of the Combined General Meeting of Shareholders of 8 April 2021 _________________________________________________________________________ I-Summary The shares concerned by the 2021-2022 buy-back programme are VINCI shares listed for trading in the A Compartment of the regulated market of NYSE Euronext in Paris under ISIN code FR0000125486. The programme offers the possibility of purchasing shares up to a maximum of 10% of the number of shares making up the Company’s share capital over a period of eighteen months from 8 April 2021 to 7 October 2022 (see duration of programme below). This limit is based on the number of shares making up the share capital at the time of the purchases. Since the programme provides for the possibility of using derivatives in performing it, the treasury shares that the Company could purchase through the exercise of the share purchase options that it may have bought previously will be included in the calculation of the maximum number of shares authorised over the eighteen-month duration of the programme, at the time of the purchase of these share purchase options, and not at the time of their exercise, if any. Maximum purchase price: €130. Maximum amount of purchases authorised: €2 billion. The purchase cost of any derivatives used by the Company in connection with the programme shall be recognised in the maximum amount authorised at the time they are put in place. The amount relating to the price of any treasury shares acquired through the exercise of share purchase options shall only be recognised at the time of their exercise. Additional amounts that may be allocated to the liquidity agreement shall be recognised in the maximum amount of purchases authorised. Objectives: (1) delivery of shares pursuant to the exercise of the rights attached to securities giving access to the share capital; (2) transfers of shares for payment or exchange purposes, in particular in connection with transactions involving external growth; (3) disposals or transfers of Company shares to eligible employees and/or company officers of VINCI Group companies in the context of savings plans or any share ownership plan governed by French or foreign law, share and/or share purchase option allocation plans; (4) ensuring market liquidity under a liquidity agreement that complies with a code of ethics recognised by the Autorité des Marchés Financiers (AMF, the French financial markets regulator) and entrusted to an investment service provider acting independently; (5) cancellation of shares; and (6) implementation of any market practice, any objective or any transaction that would be accepted under laws or regulations in force or by the AMF with respect to share buy-back programmes. Duration of the programme: eighteen months from the approval of the Combined Shareholders’ General Meeting of 8 April 2021, i.e. until 7 October 2022. II-Objectives of the 2021-2022 share buy-back programme: use of shares purchased VINCI wishes to implement a new share buy-back programme with the objectives described below. 1. Fulfilment of obligations to transfer or exchange shares pursuant to the exercise of the rights attached to securities giving access to the Company’s share capital. 2. Transfers of shares for payment or exchange purposes, in particular in connection with transactions involving external growth. 3. Disposals or transfers of Company shares to eligible employees and/or company officers of VINCI Group companies in the context of savings plans or any share ownership plan governed by French or foreign law, share and/or share purchase option allocation plans, including disposals to any approved service provider appointed to design, implement and manage any employee savings UCITS or similar employee savings structure on behalf of the VINCI Group, and pledges of shares as guarantees under employee savings plans. 4. Market-making through a liquidity agreement that complies with a code of ethics recognised by the AMF and entrusted to an investment service provider acting independently. 5. Cancellation, as part of the Company’s financial policy, of the shares thus purchased, subject to the adoption of the twelfth resolution of the 8 April 2021 Shareholders’ General Meeting. 6. Implementation of any market practice, any objective or any transaction that would be accepted under laws or regulations in force or by the AMF with respect to share buy-back programmes. The shares purchased and retained by VINCI shall not carry any voting rights and shall not give right to the payment of dividends. The Company reserves the right to use derivatives in implementing this new programme. Furthermore, in compliance with the applicable legal and regulatory provisions, including those relating to stock exchange disclosure requirements, it reserves the right to carry out authorised reallocations of shares purchased in view of one of the programme’s objectives to one or more of its other objectives, or to sell them on-market or off-market through an investment service provider acting independently. III-Legal framework This programme is within the framework of the provisions of Articles L.22-10-62 et seq. and Articles L.225-210 to L.225-212 of the French Commercial Code and shall be submitted on 8 April 2021 to VINCI’s Shareholders’ General Meeting, acting in accordance with the quorum and majority requirements for ordinary (sixth resolution) and extraordinary (twelfth resolution) shareholders’ meetings: Sixth resolution Renewal of the delegation of powers to the Board of Directors in view of the purchase by the Company of its own shares The Shareholders’ General Meeting, having taken note of (a) the Report of the Board of Directors and (b) the description of the new 2021-2022 share buy-back programme, in accordance with the provisions of Articles L.22-10-62 et seq. and Articles L.225-210 et seq. of the French Commercial Code as well as European regulation 596/2014 of 16 April 2014 on market abuse, authorises the Board of Directors, with the ability to sub-delegate such powers, within the limits provided for by law and regulations, on one or more occasions, on the stock market or otherwise, including by blocks of shares or through the use of options or derivatives, to purchase the Company’s shares for the conduct of the following: 1. transfer or exchange of shares upon the exercise of the rights attached to securities giving access to the Company’s share capital; 2. retention and future delivery for payment or exchange purposes in connection with transactions involving external growth; 3. disposal or transfer of Company shares to eligible employees and/or company officers of VINCI Group companies in the context of savings plans or any share ownership plan governed by French or foreign law, share and/or share purchase option allocation plans, including disposal to any approved service provider appointed for the design, implementation and management of any employee savings UCITS or similar structure on behalf of the VINCI Group, and pledge of shares as guarantee under employee savings plans; 4. ensuring market liquidity within the framework of a liquidity agreement that complies with a code of ethics recognised by the Autorité des Marchés Financiers and entrusted to an investment service provider acting independently; 5. cancellation, as part of the Company’s financial policy, of the shares thus purchased, subject to the adoption of the twelfth resolution hereunder; 6. implementation of any market practice, any objective or any transaction that may be accepted by laws or regulations or in force or by the Autorité des Marchés Financiers in respect of share buy-back programmes. The maximum purchase price per share is set at €130. The maximum number of shares purchased by virtue of this authorisation shall not exceed 10% of the share capital. This limit is calculated at the time of the purchases and the maximum amount of shares thus purchased shall not exceed €2 billion. The share purchase price shall be adjusted by the Board of Directors in the event of transactions involving the Company’s capital in compliance with the conditions provided for by the applicable regulations. In particular, in the event of a capital increase through the capitalisation of reserves and the allotment of performance shares, the price specified above shall be adjusted by a multiplier equal to the ratio of the number of shares making up the share capital before the transaction to the number of shares after the transaction. The acquisition, disposal, transfer, allotment or exchange of these shares may be carried out by any means that are authorised or that may become authorised by regulations in force, either on-market or off-market, including block transactions or through the use of derivatives, in particular through share purchase options in accordance with the regulations in force. There is no restriction on the proportion of the share buy-back programme that may be carried out through block transactions. These transactions may be carried out at any time in compliance with the current regulations, except during a public offering period. The Shareholders’ General Meeting grants full powers to the Board of Directors, including the ability to delegate such powers, so that, in compliance with the applicable legal and regulatory provisions, including those on stock exchange disclosure requirements, it may proceed with the authorised reallocations of the shares purchased in view of one of the programme’s objectives to one or more of its other objectives, or sell them on-market or off-market, it being specified that these reallocations and disposals may concern shares purchased pursuant to previously authorised share buy-back programmes. The Shareholders’ General Meeting grants full powers to the Board of Directors, including the ability to delegate such powers, for the purpose of placing stock market orders, signing any deed of purchase, sale or transfer, entering into any agreement, carrying out any necessary adjustments, making all declarations and completing all formalities. This authorisation is granted for a period of eighteen months from the date of this Shareholders’ General Meeting. It renders ineffective and replaces the authorisation granted by the Shareholders’ General Meeting on 18 June 2020 in its sixth resolution. Twelfth resolution Renewal of the authorisation granted to the Board of Directors in view of the reduction of the share capital through cancellation of VINCI shares held in treasury The Shareholders’ General Meeting, voting under the quorum and majority conditions required for Extraordinary Shareholders’ General Meetings, having considered the Report of the Board of Directors and the Special Report of the Statutory Auditors, in accordance with the provisions of Article L.22-10-62 of the French Commercial Code, authorises the Board of Directors to cancel, at its sole discretion, on one or more occasions, within the limit of 10% of the number of shares making up the share capital on the date when the Board of Directors takes a decision to cancel and over successive periods of twenty-four months for the determination of this limit, the shares purchased by virtue of the authorisations granted to the Company to purchase its own shares, and to proceed with a reduction in share capital equivalent to that amount. The Shareholders’ General Meeting establishes the validity of this authorisation at twenty-six months as from the date of the present meeting and grants full powers to the Board of Directors, including the powers to delegate such powers, to take all decisions necessary for the cancellation of shares and reduction of the share capital, to recognise the difference between the purchase price and the nominal value of the shares in the reserve account of its choice, including the account for “share premiums arising on contributions or mergers”, to perform all actions, formalities or declarations to finalise the reductions in capital which may be carried out by virtue of this authorisation, and to amend the Company’s Articles of Association accordingly. This authorisation renders ineffective and replaces the authorisation granted by the Shareholders’ General Meeting on 18 June 2020 in its eleventh resolution. IV-Arrangements 1. Maximum proportion of the share capital that may be acquired and maximum amount payable by VINCI The maximum proportion of the share capital that VINCI may acquire is 10% of the share capital on the date of the Combined Shareholders’ General Meeting. However, in the event of a change in the share capital after that date, the authorisation granted by the General Meeting would apply to 10% of the new share capital. The maximum purchase price per share is set at €130. The maximum total amount of capital that may be allocated to share purchases by virtue of this programme amounts to €2 billion. This maximum amount shall apply for all transactions carried out from 8 April 2021 over the duration of the programme: purchases of treasury shares, acquisitions of derivatives on treasury shares, treasury share subscriptions through the exercise of derivatives previously put in place, additional amounts that may be allocated to the liquidity agreement. The Company reserves the right to use the entire programme. VINCI shall ensure that it does not directly or indirectly exceed the buy-back ceiling of 10% of the share capital authorised by the Shareholders’ General Meeting over the programme’s eighteen-month term. It shall furthermore ensure that it does not own at any time, directly or indirectly, more than 10% of its share capital. Moreover, the share buy-back programme shall not have any significant impact on VINCI’s free float, which amounted to 82.8% of the share capital on 31 December 2020. The amount of the Company’s available reserves, which was €29,217 million at 31 December 2020, is, as required by law, higher than the amount of the share buy-back programme. 2. Share buy-back arrangements Shares may be purchased fully or partly by any means that are authorised or that may become authorised by regulations in force, either on-market or off-market, including block transactions or through the use of derivatives, including through share purchase options in accordance with regulations in force. The Company shall be careful not to increase the volatility of its share price if it uses derivatives. These transactions may be carried out at any time in compliance with the current regulations, except during a public offering period. The proposed authorisation submitted to the General Meeting does not restrict the proportion of the programme that may be carried out through the acquisition of blocks of shares. 3. Duration and timeframe of the share purchase and cancellation programme Share purchases may be carried out over a period of eighteen months following the date of the Shareholders’ General Meeting, i.e. from 8 April 2021 until 7 October 2022. Pursuant to paragraph 4 of Article L.22-10-62 of the French Commercial Code, the shares purchased can only be cancelled up to a limit of 10% of the share capital over successive rolling periods of twenty-four months. 4. Use of derivatives VINCI reserves the right to use derivatives for the implementation of this programme in order to cover, under current regulations, option positions that it has taken separately (such as share subscription or purchase options granted or issued debt securities giving access to the share capital). Information on the use of derivatives on treasury shares is systematically provided to the Board of Directors. Board of Directors of VINCIand, by delegation of the Board of Directors, ________________________ Xavier HuillardChairman and Chief Executive Officer 1 March 2021 This document, which constitutes the 2021-2022 share buy-back programme submitted for the approval of VINCI’s Shareholders’ General Meeting on 8 April 2021, is available free of charge on request from:VINCI Shareholder Relations Department1 cours Ferdinand de Lesseps, 92851 Rueil Malmaison Cedex, France It is available online on the VINCI website (www.vinci.com) and has been filed with the Autorité des Marchés Financiers. Attachment 20210120_Descriptif_PRA_2021-2022_v20012021dg
Communiqué de presse – 4 mars 2021 – 17h45 Modalités de mise à disposition des documents préparatoires à l’Assemblée Générale Mixte du 25 mars 2021 Les actionnaires de la société ARGAN sont informés que l’Assemblée Générale Mixte, qui se tiendra le jeudi 25 mars 2021 à 14 heures 30, est convoquée à huis clos, hors la présence physique des actionnaires, de leurs mandataires et de toute autre personne ayant le droit d’y assister compte-tenu des circonstances exceptionnelles liées à la pandémie de la Covid-19 et conformément aux dispositions de l’ordonnance n°2020-321 du 25 mars 2020 (telle que prorogée et modifiée par l’ordonnance n°2020-1497 du 2 décembre 2020). L’assemblée sera retransmise en direct, et accessible en différé, sur le site Internet de la société (www.argan.fr). L’avis de réunion comportant l’ordre du jour et le projet des textes de résolutions a été publié au BALO du 17 février 2021 (bulletin n°21). L’avis de convocation sera publié au BALO du 5 mars 2021 (bulletin n°28), ainsi qu’aux Affiches Parisiennes du 5 mars 2021. Les modalités de participation et de vote à cette assemblée figurent dans ces avis. Compte-tenu du contexte, les actionnaires sont invités à envoyer leurs questions écrites à l’adresse email@example.com au plus tard jusqu’à la fin du deuxième jour ouvré précédant la date de l’assemblée générale, soit le mardi 23 mars 2021. Les réponses apportées à ces questions par le Président du Directoire en séance seront publiées sur le site Internet de la société dès que possible à l’issue de l’assemblée et, au plus tard, avant la fin du cinquième jour à compter de la date de l’assemblée. Les informations ou documents relatifs à l’Assemblée Générale Mixte peuvent être consultés sur le site Internet d’Argan, à l’adresse suivante : www.argan.fr, rubrique Espace Investisseurs / Assemblées Générales. Conformément aux dispositions légales et réglementaires applicables : tout actionnaire nominatif peut, jusqu’au cinquième jour inclusivement avant l’Assemblée, demander à la Société de lui envoyer les documents et renseignements mentionnés aux articles R.225-81 et R.225-83 du code de commerce. Pour les titulaires d’actions au porteur, l’exercice de ce droit est subordonné à la fourniture d’une attestation de participation dans les comptes de titres au porteur tenus par l’intermédiaire habilité ; tout actionnaire peut prendre connaissance des documents visés aux articles L.225-115, L.225-116, R.225-83 et R.225-89 du code de commerce au siège de la Société pendant un délai de 15 jours précédant la date de l’Assemblée. Argan précise que ces documents sont librement accessibles et consultables sur son site internet www.argan.fr dans la rubrique Espace Investisseurs / Assemblées Générales, et notamment : le rapport du Directoire sur la gestion de la Société et l’activité du Groupe au cours de l’exercice annuel clos le 31 décembre 2020,le rapport du Conseil de Surveillance sur le gouvernement d’entreprise,les comptes sociaux et consolidés de l’exercice annuel clos le 31 décembre 2020,les rapports des commissaires aux comptes de la Société sur les comptes sociaux et consolidés de l’exercice annuel clos le 31 décembre 2020. Calendrier financier 2021 (Diffusion du communiqué de presse après bourse) 25 mars : Assemblée Générale annuelle1er avril : Chiffre d’affaires du 1er trimestre 20211er juillet : Chiffre d’affaires du 2ème trimestre 202115 juillet : Résultats semestriels 20211er octobre : Chiffre d’affaires du 3ème trimestre 2021 A propos d’Argan ARGAN est l’unique foncière française de DEVELOPPEMENT & LOCATION D’ENTREPOTS PREMIUM cotée sur Euronext.Au 31 décembre 2020, son patrimoine représente 3 millions de m², se décomposant en 87 entrepôts implantés en France exclusivement, valorisé 3 Mds€ et générant 152 M€ de revenus locatifs annualisés. ARGAN est cotée sur le compartiment A d’Euronext Paris (ISIN FR0010481960 – ARG) et fait partie des indices CAC All-Shares et IEIF SIIC France. La foncière a opté pour le régime des SIIC au 1er juillet 2007. Francis Albertinelli - Directeur Administratif et FinancierMarie-Caroline Schwartz – Secrétaire GénéraleTél : 01 47 47 05 46 E-mail : firstname.lastname@example.org Aude Vayre – Relations presse Tél : 06 14 64 15 65 Philippe Ronceau – Relations Investisseurs Tél : 06 64 12 53 61 E-mail : email@example.com Attachment 20210304 - Argan - Mise à disposition documents AG 25032021
This evolutionary throwback is called "freeze and appease" — and it isn't doing your health or relationships any favors.